Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Phase 2 Completed 21 enrolled TG Therapeutics, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

Timeline

Start: 2017-11-30
Primary completion: 2022-02-15
Completion: 2022-02-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Umbralisib	Small molecule	800 mg	Oral

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Summary

Timeline

Drugs

Indications